Greenland Mines Ltd GRML

US Biotechnology
$0.19 โ–ผ -1.17% ($0.00)
🎢 High Beta
Open $0.20
Prev Close $0.20
Day Range $0.18 โ€“ $0.20
52W Range $0.16 โ€“ $0.55
Market Cap $29.68M
Beta 2.52
EPS (TTM) $-0.34

๐Ÿ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date2022-04-29
Shares Out.150,530,000
Websitegreenlandmines.com โ†—
Phone13028948922
Employees5
Net Income-$13.9M
Total Assets$59.7M
Total Liabilities$8.3M
Equity$51.5M
About Greenland Mines Ltd

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Greenland Mines Ltd is a publicly traded company under the ticker symbol GRML on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

๐Ÿ“ฐ Latest News for GRML

๐Ÿ‘ฅ Related Stocks